

DR. JÖRG C. MAHLICH

Market Access & Government Affairs Lead

Miltenyi Biomedicine

Friedrich-Ebert-Straße 68

51429 Bergisch Gladbach, Germany

E-mail: joergma@miltenyi.com

WORK EXPERIENCE

- 2021-currently MARKET ACCESS & GOUVERNMENT AFFAIRS LEAD, [MILTENYI BIOMEDICINE](#), Bergisch Gladbach, DE
- 2017-2021 HEAD HEALTH ECONOMICS AND OUTCOMES RESEARCH, [JANSSEN-CILAG](#) [Johnson & Johnson], Neuss, DE
- 2014-2017 DIRECTOR HEALTH ECONOMICS, [JANSSEN PHARMACEUTICAL](#) [Johnson & Johnson], Tokyo, JP
- 2012-2014 MARKET ACCESS LEAD, [JANSSEN THERAPEUTICS EMEA](#) [Johnson & Johnson], Neuss, DE
- 2010-2014 MANAGER HEALTH ECONOMICS & REIMBURSEMENT, [JANSSEN-CILAG](#) [Johnson & Johnson], Neuss, DE
- 2004-2010 ADVISOR, [AUSTRIAN ECONOMIC CHAMBER](#), Vienna, AT
- 2001-2003 CONSULTANT, [TECHNOPOLIS](#), Vienna, AT
- 2001 CONSULTANT, [UNITED NATIONS DEVELOPMENT ORGANIZATION](#), Vienna, AT
- 1998-2000 PhD RESEARCHER, [AUSTRIAN INSTITUTE OF TECHNOLOGY](#), Seibersdorf, AT
- 1997 INTERN, [BAYER YAKUHIN](#), Osaka, JP
- 1996-1997 TRAINEE, [GERMAN CHAMBER OF COMMERCE AND INDUSTRY IN JAPAN](#), Osaka, JP

PROFESSIONAL ACTIVITIES

- 2017 VICE CHAIRMAN, ACCESS COMMITTEE, [EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES AND ASSOCIATIONS \(EFPIA JAPAN\)](#), Tokyo, JP
- 2009-2010 HEAD HEALTH ECONOMIC ADVISORY BOARD, [AMGEN](#), Vienna, AT

ACADEMIC POSITIONS

2008 - currently LECTURER, [UNIVERSITY OF VIENNA](#), Vienna, AT

- [DEPARTMENT OF ECONOMICS](#)
 - o [UK Health and Pharmaceutical Economics \(LV 040760\)](#): Summer 2023, 2022, 2021, 2020, 2019, 2018, 2014, 2013, 2012, 2011, 2010, 2009, 2008.
 - o VO Introduction to Economics (LV 040242): Winter 2013, 2012, 2011, 2010.
 - o UE Introduction to Economics (LV 040244): Winter 2013, 2012, 2011, 2010.
- [DEPARTMENT OF EAST ASIAN STUDIES](#)
 - o VO Japanese Economy (LV 150008): Summer 2010, 2009.

2014 - currently RESEARCH AFFILIATE, [HEINRICH-HEINE-UNIVERSITY DÜSSELDORF](#), Düsseldorf, DE

- [DÜSSELDORF INSTITUTE FOR COMPETITION ECONOMICS \(DICE\)](#)

2018 - 2019 GUEST LECTURER, [JUSTUS LIEBIG UNIVERSITY GIESSEN](#), Giessen, DE.

- [HESSEN INTERNATIONAL SUMMER UNIVERSITY](#)
 - o Summer Course: Innovation and Regulation in Pharma and Medtech: Summer 2019, 2018.

2012 GUEST LECTURER, [EBERHARD-KARLS-UNIVERSITÄT](#), Tübingen, DE

- [DEPARTMENT OF INTERNATIONAL BUSINESS](#)
 - o SE Doing Business in Japan (LV SQ463): Summer 2012.

2007-2012 LECTURER, [UNIVERSITY OF APPLIED SCIENCES FOR MANAGEMENT AND COMMUNICATION](#), Vienna, AT

- [DEPARTMENT OF HUMAN RESSOURCES AND ORGANISATION](#)
 - o Economics (LV 05151202): Winter 2010, 2009, 2008, 2007.
- [DEPARTMENT FOR TOURISM AND HOSPITALITY MANAGEMENT](#)
 - o Economics (LV 02591115): Winter 2010, 2009, 2008.
 - o Business Economics (LV 02593105): Winter 2011, 2010, 2009.

SCHOLARSHIPS

2010 [UNIVERSIDAD AUTONOMA DE MADRID, CENTRO DE ESTUDIOS DE ASIA ORIENTAL \(ERASMUS +\)](#).

2008 [UNIVERSITY OF KOBE, RESEARCH INSTITUTE FOR ECONOMICS & BUSINESS ADMINISTRATION \(JAPANESE SOCIETY FOR THE PROMOTION OF SCIENCES\)](#).

EDUCATION (Economics)

2000 Dr ([UNIVERSITY OF VIENNA](#))

1995 Diplom (Master) ([UNIVERSITY OF KIEL](#))

1992 Academic summer session ([UNIVERSITY OF CALIFORNIA LOS ANGELES](#))

JOURNALS

Borchmann P, Heger J-M, Mahlich J, Papadimitriou M, Riou S, Werner B (2023) [Survival outcomes of patients diagnosed with diffuse large B-cell lymphoma - Real world evidence from Germany](#), *Journal of Cancer Research and Clinical Oncology*, <https://doi.org/10.1007/s00432-023-04660-y>

Scheid C, Kudernatsch R, Eckart M, Feig C, Libutzki B, Mahlich J (2023) [Incidence of graft-versus-host-disease in Germany: evidence from health care claims data](#), *Journal of Public Health*, <https://doi.org/10.1007/s10389-022-01736-w>.

Fischer P, Reiss T, Mahlich J, Gicquel E, Aichinger H, Pullmann L, Bratan T (2023) [Unlocking the value of innovative medicines: comparison of advanced technology medicinal products \(ATMP\) innovation systems in Germany and Sweden](#), *Health Policy and Technology*, <https://doi.org/10.1016/j.hlpt.2023.100744>

Kemper M, Mahlich J (2023) [Zahlungsbereitschaft für Insektizid-imprägnierte Moskitonetze zur Malariaphylaxe in Subsahara-Afrika – eine systematische Literaturrecherche](#), *Gesundheitsökonomie und Qualitätsmanagement*, <https://doi.org/10.1055/a-2029-3398>.

Inoue Y, Oka S, Yokoyama S, Hasegawa K, Mahlich J, Schaede U, Murata Y, Habuka N (2023) [Medication adherence of people living with HIV in Japan – a cross-sectional study](#), *Healthcare* 11(4):451.

Borchmann P, Heger J-M, Mahlich J, Papadimitriou M, Riou S, Werner B (2023) [Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma – A Retrospective Health Claims Data Analysis](#), *Oncology and Therapy* 11(1):83-96.

Käffer A, Mahlich J (2022) [Culture and COVID-19 related mortality - a cross sectional study of 50 countries](#), *Journal of Public Health Policy* 43(3):413-430.

Sewerin P, Borchert K, Meise D, Schneider M, Mahlich J (2022) [Health resource utilization and associated healthcare costs of biologic disease modifying antirheumatic drugs in German patients with psoriatic arthritis](#), *Arthritis Care and Research* 74(9):1435-1443.

Scheid C, Kudernatsch R, Eckart M, Feig C, Straub V, Libutzki B, Mahlich J (2022) [Treatment pathways and health outcomes of German patients with chronic Graft versus host disease after allogeneic hematopoietic cell transplantation – A retrospective health claims data analysis](#), *Drugs - Real World Outcomes* 9(4):577-588.

Treskova M, Scholz S, Kuhlmann A, Mahlich J, Stoll M (2022) [Estimation of utility values and factors driving health-related quality of life in people living with HIV and AIDS and receiving cART in Germany: baseline analysis of a cohort study](#), *Applied Research in Quality of Life* 17(2):851-869.

Augustin M, Wirth D, Mahlich J, Pepper A, Druchok C (2022) [Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany](#), *Journal of Dermatological Treatment* 33(2):976-982.

Mahlich J, Bartol A, Dheban S (2021) [Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis](#), *Health Economics Review* 11:4.

Mahlich J, Olbrich K, Wilk A, Wimmer A, Wolff-Menzler C (2021) [Time to treatment discontinuation in German patients with Schizophrenia: Long acting injectables versus oral antipsychotics](#), *Clinical Drug Investigation* 41(1):99-113.

- Mahlich J, May M, Feig C, Straub V, Schmelz R (2021) [Persistence with biologic therapy and associated costs of patients with Inflammatory Bowel Disease: A German retrospective claims data analysis](#), *Crohn's & Colitis* 360 3(2):otab011.
- Mahlich J, Dheban S (2021) [Bright Line or Lottery? On significance and value in medical decision making](#), *Journal of Market Access and Health Policy* 9(1):1981574.
- Sewerin P, Borchert K, Meise D, Schneider M, Mahlich J (2021) [Real World Treatment Persistence with Biologic Disease Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis - A Retrospective Database Study](#), *Rheumatology and Therapy* 8(1):483-497.
- Wolff-Menzler C, Mahlich J, Olbrich K, Wilk A, Wimmer A (2021) [Hospitalisierungen und Behandlungskosten von Schizophreniepatienten nach Umstellung auf Depot-Antipsychotika](#), *Gesundheitsökonomie und Qualitätsmanagement* 26(6):302-309.
- Miyazaki C, Sruamsiri R, Mahlich J, Jung W (2020) [Treatment Patterns and Health Care Utilization in Palmoplantar Pustulosis Patients in Japan: a Claims Database Study](#), *PLOS ONE* 15(5):e0232738.
- Miyazaki C, Sruamsiri R, Mahlich J, Jung W (2020) [Treatment Patterns and Medical Cost of Systemic Lupus Erythematosus Patients in Japan: A Retrospective Claims Database Study](#), *Journal of Medical Economics* 23(7):786-799.
- McDougall J, Furnback W, Wang B, Mahlich J (2020) [Understanding the Global Measurement of Willingness to Pay in Health](#), *Journal of Market Access and Health Policy* 8(1):1717030.
- Mahlich J, Olbrich K, Wilk A, Wimmer A, Wolff-Menzler C (2020) [Hospitalization Rates and Therapy Costs of German Schizophrenia Patients who are Initiated on Long-acting Injectable Medication: A Mirror Image Study](#), *Clinical Drug Investigation* 40(4):355–375.
- Mahlich J, Yurtoglu B (2019) [Returns on different types of investment in the global pharmaceutical industry](#), *Managerial and Decision Economics* 40(1):16-36.
- Mahlich J, Sindern J, Suppliet M (2019) [Cross-national drug price comparisons with economic weights in external reference pricing in Germany](#), *Expert Review of Pharmacoeconomics & Outcomes Research* 19(1):37-43.
- Mahlich J, Sruamsiri R (2019) [Co-insurance and health care utilization in Japanese patients with rheumatoid arthritis: a discontinuity regression approach](#), *International Journal for Equity in Health* 18:13.
- Bolt T, Kobayashi H, Mahlich J (2019) [Patient and Physician Preferences for Therapy Characteristics for Psoriasis: A Discrete Choice Experiment in Japan](#), *Pharmacoeconomics – Open* 3(2):255–264.
- Mahlich J, Alba A, El Hadad L, Leisten M-K, Peitsch W (2019) [Drug survival of biological therapies for psoriasis treatment in Germany and associated costs: a retrospective claims database analysis](#), *Advances in Therapy* 36(7):1684–1699.
- Mahlich J, Schaede U, Sruamsiri R (2019) [Shared Decision-Making and Patient Satisfaction in Japanese Rheumatoid Arthritis Patients: A New 'Preference Fit' Framework for Treatment Assessment](#), *Rheumatology and Therapy* 6(2):269-283.
- Nakamura Y, Shibata I, Mahlich J (2019) [Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital](#), *Neurology and Therapy* 8(2):433-447.

- Mahlich J, Dilokthornsakul P, Sruamsiri R, Chaiyakunapruk N (2018) [Cultural beliefs, utility values, and health technology assessment](#), *Cost Effectiveness and Resource Allocation* 16:19.
- Bolt T, Mahlich J, Nakamura Y, Nakayama M (2018) [Hematologists' preferences for first-line therapy characteristics for multiple myeloma in Japan: Attribute Rating and Discrete Choice Experiment](#), *Clinical Therapeutics* 40:296-308.
- Sruamsiri R, Mori Y, Mahlich J (2018) [Productivity loss of caregivers of schizophrenia patients: a cross-sectional survey in Japan](#), *Journal of Mental Health* 27(6):583-587.
- Mahlich J, Kamae I, Sruamsiri R (2018) [Pharmaceutical Pricing in Japan: Market Evidence for Rheumatoid Arthritis Treatment](#), *Expert Review of Pharmacoeconomics & Outcomes Research* 18(3):339-348.
- Sruamsiri R, Kameda H, Mahlich J (2018) [Persistence with biological disease-modifying antirheumatic drugs and its associated resource utilization and costs](#), *Drugs - Real World Outcomes* 5(3):169-179.
- Sruamsiri R, Mahlich J, Tanaka E, Yamanaka H (2018) [Productivity loss of Japanese patients with rheumatoid arthritis – a cross-sectional survey](#), *Modern Rheumatology* 28(3):482-489.
- Cheung S, Hamuro Y, Mahlich J, Nakayama M, Tsubota A (2018) [Treatment pathways of Japanese prostate cancer patients - a retrospective transition analysis with administrative data](#), *PLOS ONE* 13(4):e0195789.
- Schaede U, Mahlich J, Nakayama M, Kobayashi H, Takahashi Y, Saito K, Uemura H, Tokumitsu M, Yoshizawa K (2018) [Shared Decision-Making in Prostate Cancer Treatment in Japan: Patient Preferences Versus Physician Perceptions](#), *Journal of Global Oncology* 4:1-9.
- Mahlich J, Tsubota A, Imanaka K, Enjo K (2018) [Burden of illness of chemotherapy in castration-resistant prostate cancer patients in Japan: a retrospective database analysis](#), *Current Medical Research and Opinion* 34(10):1855-1860.
- Mahlich J, Matsuoka K, Sruamsiri R (2018) [Biologic Treatment of Japanese Patients with Inflammatory Bowel Disease](#), *BMC Gastroenterology* 18:160.
- Sruamsiri R, Kubo H, Mahlich J (2018) [Hospitalization costs and length of stay of Japanese children with respiratory syncytial virus: A structural equation modeling approach](#), *Medicine* 97(29):e11491.
- Sruamsiri R, Iwasaki K, Tang W, Mahlich J (2018) [Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database](#), *BMC Dermatology* 18:5.
- Nakayama M, Kobayashi H, Okazaki M, Imanaka K, Yoshizawa K, Mahlich J (2018) [Patient preferences and urologist judgments on prostate cancer therapy in Japan](#), *American Journal of Men's Health* 12(4):1094-1101.
- Guelfucci F, Kaneko Y, Mahlich J, Sruamsiri R (2018) [Cost of Depression in Japanese Patients with Rheumatoid Arthritis: Evidence from Administrative Data](#), *Rheumatology and Therapy* 5(1):171-183.
- Mahlich J, Tsukazawa S, Wiegand F (2018) [Estimating Prevalence and Health Care Utilization for Treatment Resistant Depression in Japan: a Retrospective Claims Database Study](#), *Drugs - Real World Outcomes* 5(1):35-43.
- Mahlich J, Kamae I, Rossi B (2017) [A new Health Technology Assessment System for Japan? Simulating the Potential Impact on the Price of Simeprevir](#), *International Journal of Technology Assessment in Health Care* 33(1):121-127.

- Mahlich J, Okamoto S, Tsubota A (2017) [Cost of illness of Japanese patients with chronic lymphocytic leukemia \(CLL\) and budget impact of the market introduction of ibrutinib](#), *Pharmacoeconomics - Open* 1(3):195–202.
- Cheung S, Hamuro Y, Mahlich J, Nakahara T, Sruamsiri R, Tsukazawa S (2017) [Drug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis](#), *Clinical Drug Investigation* 37(6):559-569.
- Mahlich J, Matsuoka K, Nakamura Y, Sruamsiri R (2017) [The Relationship between Socio-demographic Factors, Health Status, Treatment Type, and Employment Outcome in Patients with Inflammatory Bowel Disease in Japan](#), *BMC Public Health* 17:623.
- Sruamsiri R, Ferchichi S, Jamotte A, Toumi M, Kubo H, Mahlich J (2017) [Impact of Patient Characteristics and Treatment Procedures on Hospitalisation Cost and Length of Stay in Japanese Patients with Influenza: A Structural Equation Modelling Approach](#), *Influenza and Other Respiratory Viruses* 11(6):543–555.
- Mahlich J, Matsuoka S, Sruamsiri R (2017) [Shared decision making and treatment satisfaction in Japanese Patients with Inflammatory Bowel Disease \(IBD\)](#), *Digestive Diseases* 35(5):454-462.
- Nakamura Y, Mahlich J (2017) [Productivity and Deadweight Losses due to Relapses of Schizophrenia in Japan](#), *Neuropsychiatric Disease and Treatment* 13:1341–1348.
- Morishige R, Nakajima H, Yoshizawa K, Mahlich J, Sruamsiri R (2017) [Preferences Regarding Shared Decision-Making in Japanese Inflammatory Bowel Disease Patients](#), *Advances in Therapy* 33(12):2242-2256.
- Sruamsiri R, Kaneko Y, Mahlich J (2017) [The Underrated Prevalence of Depression in Patients with Rheumatoid Arthritis: Evidence from a Nationwide Survey in Japan](#), *BMC Rheumatology* 1:5.
- Mahlich J, Sruamsiri R (2017) [Preference for shared decision-making in Japanese patients with rheumatoid arthritis](#), *Cogent Medicine* 4:1353262.
- Mahlich J, Sruamsiri R (2017) [Treatment Patterns of Rheumatoid Arthritis in Japanese Hospitals and Predictors of the Initiation of Biologic Agents](#), *Current Medical Research and Opinion* 33(1):101-107.
- Mahlich J, Sruamsiri R (2016) [Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan](#), *Patient Preference and Adherence* 10:1509-1519.
- Hafner P, Mahlich J (2016) [Determinants of physician’s office visits and potential effects of co-payments: evidence from Austria](#), *International Journal of Health Planning and Management* 31(3):e192–e203.
- Groß M, Herr A, Hower M, Kuhlmann A, Mahlich J, Stoll M (2016) [Unemployment, health, and education of HIV-infected males in Germany](#), *International Journal of Public Health* 61(5):593-602.
- Mahlich J, Groß M, Kuhlmann A, Bogner J, Heiken H, Stoll M (2016) [The choice between a ritonavir boosted protease inhibitor and a non-nucleoside reverse transcriptase inhibitor based regimen for initiation of antiretroviral treatment – results from an observational study in Germany](#), *Journal of Pharmaceutical Policy and Practice* 9:39.
- Treskova M, Kuhlmann A, Bogner J, Hower M, Heiken H, Stellbrink H, Mahlich J, von der Schulenburg JM, Stoll M (2016) [Analysis of Contemporary HIV/AIDS Healthcare Costs in Germany: Driving Factors and Distribution across Antiretroviral Therapy Lines](#), *Medicine* 95:26(e3961).

- Andersohn F, Claes A-K, Kulp W, Mahlich J, Rockstroh J (2015) [Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison](#), *BMC Infectious Diseases* 16:10.
- Kuwabara H, Westerhout K, Treur M, Cerri K, Mahlich J, Yatsuhashi H (2015) [Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan](#), *Journal of Medical Economics* 18(7):502-511.
- Gissl C, Götz G, Mahlich J, Repp H (2015) [Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany - an application of the efficiency frontier approach](#), *BMC Infectious Diseases* 15:297.
- Mahlich J, Nishi M, Saito Y (2015) [Modelling the Budget Impact of Long Acting Injectable Paliperidone Palmitate in the Treatment of Schizophrenia in Japan](#), *ClinicoEconomics and Outcomes Research* 7:267-272.
- Kuwabara H, Saito Y, Mahlich J (2015) [Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data](#), *Neuropsychiatric Disease and Treatment* 11:935-940.
- Tomeczkowski J, Mahlich J, Stoll M (2015) [Fehlkodierungen von HIV/AIDS-Diagnosen und deren Bedeutung für den morbiditätsorientierten Risikostrukturausgleich](#), *Gesundheitsökonomie und Qualitätsmanagement* 20(3):132-139.
- Kuhlmann A, Mittendorf T, Hower M, Heiken H, Gerschmann S, Klauke S, Lutz T, Bogner J, Degen O, van Lunzen J, Bachmann C, Stellbrink H, Schmidt W, Leistner I, Mahlich J, Ranneberg B, Stoll M (2015) [Krankheitskosten von HIV-Patienten unter antiretroviraler Therapie in Deutschland - Ergebnisse einer 48-Wochen-Interimsanalyse im Rahmen der prospektiven multizentrischen Kohortenstudie ‚CORSA‘](#), *Das Gesundheitswesen* 77(6):e133-e142.
- Tomeczkowski J, Mahlich J, Stoll M (2015) [Häufigkeiten antiretroviraler Therapie in Sekundärdaten von gesetzlichen Krankenkassen in Deutschland](#), *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen/German Journal for Evidence and Quality in Health Care* 109(8):594-604.
- Mahlich J, Sindern J, Suppliet M (2015) [Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG](#), *Perspektiven der Wirtschaftspolitik* 16(2):164–172.
- Al Obaidi L, Mahlich J (2015) [A Potential Gender Bias in Assessing Quality of Life – a Standard Gamble Experiment among University Students](#), *ClinicoEconomics and Outcomes Research* 7:227-233.
- Mahlich J, Bogner J, Tomeczkowski J, Stoll M (2015) [Treatment strategies for treatment naïve HIV patients in Germany: evidence from claims data](#), *SpringerPlus* 4:306.
- Eger S, Mahlich J (2014) [Pharmaceutical regulation in Europe and its impact on corporate R&D](#), *Health Economics Review* 4:23.
- Ransmeyer S, Mehnert A, Mahlich J (2013) [Budget Impact Analyse von Paliperidon Palmitat im österreichischen Versorgungskontext](#), *PharmacoEconomics - German Research Articles* 11:25-32.
- Mühlbacher A, Stoll M, Mahlich J, Nübling M (2013) [Evaluating the Concordance of Physician Judgments and Patient Preferences on AIDS/HIV Therapy - A Discrete Choice Experiment](#), *Health Economics Review* 3:30.
- Zeidler J, Mahlich J, Greiner W, Heres S (2013) [Cost-Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany](#), *Applied Health Economics and Health Policy* 11(5):509-521.

- Mühlbacher A, Stoll M, Mahlich J, Nübling M (2013) [Patient Preferences for HIV/AIDS Therapy - A Discrete Choice Experiment](#), *Health Economics Review* 3:14.
- Fischer J, Wimmer A, Mahlich J (2013) [Medikamentenadhärenz in der Asthmatherapie – eine strukturierte Übersicht](#), *Pneumologie* 67(7):406-414.
- Dimai HP, Redlich K, Siebert U, Schneider H, Viernstein H, Mahlich J (2012) [Direkte und indirekte Kosten von osteoporotisch bedingten Frakturen in Österreich](#), *Das Gesundheitswesen* 74(10):e84-92.
- Mahlich J, Morfeld J (2012) [Berufliche Erwartungen und Erfahrungen von angehenden und berufstätigen Gesundheitsökonominnen](#), *Gesundheitsökonomie und Qualitätsmanagement* 17(6):291–296.
- Mahlich J, Stadler I (2012) [Wettbewerb zwischen Generika- und Originalherstellern in Österreich am Beispiel der ACE-Hemmer](#), *Das Gesundheitswesen* 74(1):23-28.
- Dimai HP, Redlich K, Peretz M, Borgström F, Siebert U, Mahlich J (2012) [Economic Burden of Osteoporotic Fractures in Austria](#), *Health Economics Review* 2:12.
- Mahlich J (2011) [R&D Management of Japanese Pharmaceutical Firms](#), *International Journal of Innovation and Technology Management* 8(2):211-226.
- Mahlich J, Yurtoglu B (2011) [Institutionelle Determinanten von F&E Investitionen](#), *Journal of Business Economics/Zeitschrift für Betriebswirtschaft* 81(10):1079-1107.
- Mahlich J, Yurtoglu B (2011) [Intangibles Kapital und Rentabilität in der Pharmaindustrie](#), *Die Unternehmung/Swiss Journal of Business Research and Practice* 65(1):32-49.
- Mahlich J (2010) [Patents and Performance in the Japanese Pharmaceutical Industry: an Institution-Based View](#), *Asia Pacific Journal of Management* 27(1):99-113.
- Mahlich J (2009) [Der Einfluss von Patenten auf den Unternehmenserfolg in der europäischen Pharmaindustrie](#), *Wirtschaftspolitische Blätter* 56(3):517-526.
- Mahlich J (2008) [Werbeausgaben in der Pharmaindustrie](#), *Soziale Sicherheit* 51(2):65-67.
- Mahlich J (2007) [The Japanese Pharmaceutical Industry in Transition: Has Higher Research Orientation Resulted in Higher Market Value?](#), *Asian Business & Management* 6(1):75-94.
- Mahlich J (2007) [Preisstrategien der Pharmaindustrie](#), *Soziale Sicherheit* 50(9):436-438.
- Mahlich J, Roediger-Schluga T (2006) [Determinants of Pharmaceutical R&D: Evidence from Japan](#), *Review of Industrial Organization* 28(2):145-164.
- Mahlich J, Yurtoglu B (2006) [Investitionsdeterminanten in Japan - die Rolle der Keiretsu](#), *Journal of Business Economics/Zeitschrift für Betriebswirtschaft*, Special Issue 3:25-48.
- Mahlich J (2006) [Forschungsmanagement in der Pharmaindustrie](#), *Wissenschaftsmanagement* 12(5):14-17.
- Mahlich J (2006) [Anmerkungen zur Profitabilität der Pharmaindustrie](#), *Wirtschaftswissenschaftliches Studium [WiSt]* 35(2):73-81.
- Mahlich J (2006) [Das japanische Gesundheitssystem](#), *Soziale Sicherheit* 49(12):70-76.
- Mahlich J (2005) [Erfolgsfaktoren von forschungsintensiven Firmen am Beispiel der Pharmaindustrie](#), *Die Betriebswirtschaft/Business Administration Review* 65(4):396-410.

Mahlich J (2005) [Wirtschaftspolitik für wissensintensive Branchen am Beispiel der Pharmaindustrie](#), *Zeitschrift für Wirtschaftspolitik* 54(3):366-387.

Schelenz M, Mahlich J (2005) [Selbstbeteiligungen als Reformoption für die gesetzliche Krankenversicherung in Österreich](#), *Wirtschaftspolitische Blätter* 52(4):494-503.

Mahlich J, Zhu JM (2005) [Finanzierung und ‚corporate governance‘ in China](#), *Wirtschaftspolitische Blätter* 52(1):77-88.

Dachs B, Mahlich J (2005) [China als Standort für Forschungs- und Entwicklungseinrichtungen multinationaler Unternehmen](#), *Wirtschaftspolitische Blätter* 52(1):51-64.

BOOK CONTRIBUTIONS

Dillenburger S, Isshiki M, Mahlich J (2022) [Telemedicine in Japan – Challenges and Opportunities](#), in: Walzer S (Ed.): *Digital Health Care in Germany – Market Access for Innovations*, Heidelberg: Springer, 85-95.

Cassel D, Mahlich J (2020) [What shapes the pharmaceutical market in Japan? Institutional Framework and Challenges of the Japanese Drug Industry](#), in: Storz C, Taube M (Eds.): *Firms, Institutions, and the State in East Asia*, Marburg: Metropolis, 137-151.

Tomeczkowski J, Dillenburger S, Mahlich J (2020) [Die Bedeutung von Big Data für klinische Entwicklungen und den Marktzugang](#), in: Pfannstiel M, Da-Cruz P, Rederer E (Eds.): *Digitale Transformation von Dienstleistungen im Gesundheitswesen - Impulse für die Pharmaindustrie*, Heidelberg: Springer, 209-240.

Mahlich J (2020) [R&D Management in the Japanese Pharmaceutical Industry](#), in: Brem A, Daim T (Eds.): *Managing Medical Technological Innovations*, Singapore: World Scientific, 107-132.

Mahlich J, Pascha W (2012) [The Challenge of Innovation and Technology for Korea as a Newly Advanced Economy Revisited](#), in: Mahlich J, Pascha W (Eds.): *Korean Science and Technology in International Perspective*, Heidelberg: Springer, 1-13.

Mahlich J, Paripovic I, Yurtoglu B (2012) [Institutioneller Wandel und Reorganisation der keiretsu](#), in: Distelrath G, Menkhau H, Ölschleger HD (Eds.): *Vom Ungleichen in Japan – Untersuchungen zu wachsenden Disparitäten in Gesellschaft, Wirtschaft und Recht*, Bonn: Bier'sche Verlagsanstalt, 135-154.

Mahlich J, Pascha W (2007) [Korea as a Newly Advanced Economy and the Role of Technology and Innovation](#), in: Mahlich J, Pascha W (Eds.): *Technology and Innovation in Korea*, 2007, Heidelberg: Springer, 1-10.

Dachs B, Mahlich J, Zahradnik G (2007) [The Technological Competencies of Korea's Firms: A Patent Analysis](#), in: Mahlich J, Pascha W (Eds.): *Technology and Innovation in Korea*, Heidelberg: Springer, 135-154.

Mahlich J (2007) [Die japanische Pharmaindustrie](#), in: Moerke A, Walke A (Eds.): *Japans Zukunftsindustrien*, Heidelberg: Springer, 103-123.

Mahlich J, Kaszanits H (2007) [Die österreichische Reformbilanz](#), in: Khol A, Ofner G, Burkert-Dottolo G (Eds.): *Österreichisches Jahrbuch für Politik*, München: Oldenbourg, 75-90.

Mahlich J, Yurtoglu B (2007) [On the Determinants of M&A Performance](#), in: Bebenroth R (Ed.): *In the Wave of M&A: Europe and Japan*, München: Iudicium, 17-40.

Mahlich J (2004) Neue Entwicklungen in den Banken-Firmen Beziehungen in Japan, in: Pohl M, Wiczorek I (Eds.): *Japan: Politik und Wirtschaft*, Hamburg: Deutsches Institut für Asienstudien, 243-264.

Mahlich J (2004) Über die Evaluierung von Förderprogrammen aus dem F&E-Bereich, in: Priddat B, Theurl T (Eds.): *Risiken der Politikberatung*, Baden Baden: Nomos, 187-198.

Mahlich J (2003) Das japanische Innovationssystem im Überblick, in: Pohl M, Wiczorek I (Eds.): *Japan: Politik und Wirtschaft*, Hamburg: Deutsches Institut für Asienstudien, 193-221.

Mahlich J (2002) Probleme und Perspektiven der japanischen Pharmaindustrie, in: Pohl M, Wiczorek I (Eds.): *Japan: Politik und Wirtschaft*, Hamburg: Deutsches Institut für Asienstudien, 184-208.

EDITED BOOKS

Mahlich J, Pascha W (2012) *Korean Science and Technology in an International Perspective*, Heidelberg: Springer.

Mahlich J, Schediwy R (2008) *Zeitzeugen und Gestalter österreichischer Wirtschaftsgeschichte*, Münster: LIT Verlag.

Mahlich J, Pascha W (2007) *Technology and Innovation in Korea - Challenges of a Newly Advanced Economy*, 2007, Heidelberg: Springer.

BOOKS

Scharnagel B, Mahlich J, Beck A (2006) *Das D-A-CH-Reformbarometer: Ein Vergleich der Reformpolitik in Deutschland, Österreich und der Schweiz*, Köln: Deutscher Instituts Verlag.

Mahlich J (2001) *Innovationsdeterminanten in der Pharmaindustrie am Beispiel Japans*, Frankfurt: Peter Lang.

SELECTED PRESENTATIONS

- [World Evidence, Pricing and Access Congress](#), Amsterdam 2023
- [University of Tokyo](#), 2022
- [Bionow](#), 2022
- [Real-World Evidence, Market Access, Pricing & Reimbursement 2022 Europe](#), London 2022
- [World Evidence, Pricing and Access Congress](#), Amsterdam 2022
- [5th Pharma Pricing, Reimbursement and Market Access Conference](#), 2021
- [9th EPP Life Sciences Pricing Forum](#), Munich 2019
- [Clinical Trials Europe](#), Basel 2019
- [Healthcare Market Access and Pricing Summit](#), Frankfurt 2019
- [World Pharma Pricing and Market Access](#), Amsterdam 2019
- [3rd Annual Innovative Pharma Pricing & Market Access Strategies Summit](#), Berlin 2019
- [ISPOR Plenary Session](#), Tokyo 2018.
- [8th EPP Life Sciences Pricing Forum](#), Montreux 2018
- [Pharma Pricing & Market Access Innovation Summit](#), Berlin 2018
- [Innovative Pharma Pricing & Market Access Strategies](#), Vienna 2018.
- [World Pharma Pricing and Market Access](#), London 2018
- [6th HTA International Symposium](#), Tokyo 2017.
- [Evidence](#), London 2017
- [Real World Data Japan](#), Tokyo 2016
- [ISPOR](#), Singapore 2016

- HTAi, Tokyo 2016
- Evidence, London 2016
- [Pharma Pricing and Reimbursement Forum](#), Vienna 2016
- [Japanese Association of Pharmaceutical Medicine](#), Tokyo 2016
- Pharma Pricing and Market Access, London 2016
- [Deutsche Gesellschaft für Natur- und Völkerkunde Ostasiens](#), Tokyo 2016
- [Canon Institute of Global Studies](#), Tokyo 2015
- Evidence, London 2015
- [Kansei Gakuin University](#), Nishinomiya 2015
- WHU - Otto Beisheim School of Management, Düsseldorf 2014
- Forum Pharma, Vienna 2014
- PharmaKON, Vienna 2013
- Health Care Symposium, Vienna 2013
- [Forum Pharma](#), Vienna 2013
- [Gesundheitspolitisches Kolloquium](#), Frankfurt 2013
- [University of Giessen](#), Giessen 2012
- [Amgen Press Academy](#), Vienna 2011

MEMBERSHIPS

- Austrian Health Economics Association (ATHEA)
- International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

SCIENTIFIC COMMUNITY SERVICE

- Member International Scientific Program Committee (ISPC) for HTAi 2016 conference in Tokyo.
- Reviewer for scientific conferences (e.g. ISPOR, AIB) and academic journals such as: [Applied Economics Letters](#), [Archives of Public Health](#), [Asia Pacific Journal of Management](#), [BMC Infectious Diseases](#), [BMJ Open](#), [Clinical Epidemiology](#), [Clinical Rheumatology](#), [ClinicoEconomics and Outcomes Research](#), [Cogent Economics & Finance](#), [Dermatologic Therapy](#), [Drug Discovery Today](#), [European Journal of Health Economics](#), [European Psychiatry](#), [Expert Opinion on Pharmacotherapy](#), [Health Expectations](#), [Hepatic Medicine: Evidence and Research](#), [Implementation Sciences](#), [Industrial Health](#), [Integrative Medicine Research](#), [International Clinical Psychopharmacology](#), [International Journal for Equity in Health](#), [International Journal of General Medicine](#), [International Journal of Health Policy and Management](#), [International Journal of Technology Assessment in Health Care](#), [INQUIRY: The Journal of Health Care Organization, Provision, and Financing](#), [Journal of International Medical Research](#), [Journal of Medical Economics](#), [Lancet Regional Health](#), [Managerial and Decision Economics](#), [Neuropsychiatric Disease and Treatment](#), [Open Forum Infectious Diseases](#), [Patient Preference and Adherence](#), [Patient Related Outcome Measures](#), [PLOS ONE](#), [Psoriasis: Targets and Therapy](#), [Quality of Life Research](#), [Research in Social and Administrative Pharmacy](#), [Review of Managerial Science](#), [Rheumatology International](#), [Sage Open Medicine](#), [Seminars in Arthritis and Rheumatism](#), [Technological Forecasting & Social Change](#), [The Pediatric Infectious Disease Journal](#), [Therapeutics and Clinical Risk Management](#), [Value in Health Regional Issues](#), [Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen](#)
- Co-organizer of two conferences on innovation in Korea in Vienna (2005 and 2009).
- Editor 'Wirtschaftspolitische Blätter' (2005-2010).